New antibody WIN378 aims to tame COPD lung inflammation

NCT ID NCT07646587

Recruiting now Disease control Sponsor: Windward Bio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a new medicine called WIN378 for people with moderate to severe COPD. WIN378 is a long-acting antibody that blocks a protein involved in lung inflammation. The study will test different doses in 105 adults who are former smokers and already on standard triple therapy, to see if it is safe and helps control COPD.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: WIN378 (a long-acting antibody that blocks a protein called TSLP to reduce lung inflammation)
What this could lead to: If successful, this could lead to a new, longer-lasting treatment option for people with moderate to severe COPD, helping to control symptoms and reduce flare-ups.
What could go wrong: This is an early phase 2 trial with only 105 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset Inflammation Respiration Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

WB Contracted Clinical Research Site
RECRUITING

Miami Lakes, Florida, 33014, United States
WB Contracted Clinical Research Site
RECRUITING

North Dartmouth, Massachusetts, 02747, United States
WB Contracted Clinical Research Site
RECRUITING

Charlotte, North Carolina, 28277, United States
WB Contracted Clinical Research Site
RECRUITING

McKinney, Texas, 75069, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.